GURUFOCUS.COM » STOCK LIST » USA » NAS » OncoCyte Corp (NAS:OCX) » Definitions » 5-Year EBITDA Growth Rate
Switch to:

OncoCyte (NAS:OCX) 5-Year EBITDA Growth Rate

: -7.40% (As of Sep. 2022)
View and export this data going back to 2015. Start your Free Trial

OncoCyte's EBITDA per Share for the three months ended in Sep. 2022 was $-0.07.

During the past 3 years, the average EBITDA Per Share Growth Rate was -26.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of OncoCyte was 8.80% per year. The lowest was -26.00% per year. And the median was 3.25% per year.


Competitive Comparison

For the Biotechnology subindustry, OncoCyte's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

OncoCyte 5-Year EBITDA Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where OncoCyte's 5-Year EBITDA Growth Rate falls in comparison to its industry or sector. The grey bar indicates the 5-Year EBITDA Growth Rate's extreme value range as defined by GuruFocus.



OncoCyte 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


OncoCyte  (NAS:OCX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


OncoCyte 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of OncoCyte's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (NAS:OCX) Business Description

OncoCyte logo
Industry
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Executives
Paulsen Gisela officer: Chief Operating Officer 5505 ENDEAVOR LANE MADISON WI 53719
Yu Li officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE. NEWPORT BEACH CA 92660
Carter Jennifer L. director C/O DFP SPONSOR LLC 780 THIRD AVENUE, 37TH FLOOR NEW YORK NY 10017
Ross Douglas T. officer: Chief Medical Officer 15 CUSHING IRVINE CA 92618
Kamen Efrem 10 percent owner C/O PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET, 7TH FLOOR NEW YORK NY 10011
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET 7TH FLOOR NEW YORK NY 10011
Kalajian Tony T officer: SVP-Chief Accounting Officer 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Griffith Melinda director 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Sundar Padma officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Andrews Ronald Asbury director 5791 VAN ALLEN WAY CARLSBAD CA 92008
Parker Albert P officer: Chief Operating Officer C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501
Levine Mitchell S officer: Chief Financial Officer ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO CA 94111
Hesterberg Lyndal K. officer: Sr VP, Research & Development 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Bailey Don M director 1300 N. KELLOGG DRIVE SUITE D ANAHEIM CA 92607
Bradsher Neal C 10 percent owner

OncoCyte (NAS:OCX) Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership